MA33742B1 - Co-cristaux de tramadol et de coxibs - Google Patents

Co-cristaux de tramadol et de coxibs

Info

Publication number
MA33742B1
MA33742B1 MA34859A MA34859A MA33742B1 MA 33742 B1 MA33742 B1 MA 33742B1 MA 34859 A MA34859 A MA 34859A MA 34859 A MA34859 A MA 34859A MA 33742 B1 MA33742 B1 MA 33742B1
Authority
MA
Morocco
Prior art keywords
tramadol
coccip
multiple crystals
crystals
crystal
Prior art date
Application number
MA34859A
Other languages
Arabic (ar)
English (en)
Inventor
Salaman Carlos Ramon Plata
Nicolas Tesson
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/007451 external-priority patent/WO2010043412A1/fr
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA33742B1 publication Critical patent/MA33742B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des co-cristaux de tramadol et d'agents de formation de co-cristaux choisis parmi les anti-inflammatoires non stéroïdiens (ains)/coxibs, sur leurs procédés de préparation et sur leurs utilisations comme médicaments ou dans des formulations pharmaceutiques, plus particulièrement pour le traitement de la douleur. Dans un mode de réalisation privilégié, le co-cristal est le (rac) - tramadol. Hci - célécoxib (1:1).
MA34859A 2009-10-16 2012-05-11 Co-cristaux de tramadol et de coxibs MA33742B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2009/007451 WO2010043412A1 (fr) 2008-10-17 2009-10-16 Co-cristaux de tramadol et d’ains
PCT/EP2010/002385 WO2011044962A1 (fr) 2009-10-16 2010-04-19 Co-cristaux de tramadol et de coxibs

Publications (1)

Publication Number Publication Date
MA33742B1 true MA33742B1 (fr) 2012-11-01

Family

ID=42272447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34859A MA33742B1 (fr) 2009-10-16 2012-05-11 Co-cristaux de tramadol et de coxibs

Country Status (19)

Country Link
US (1) US20230057884A1 (fr)
JP (1) JP5399564B2 (fr)
KR (1) KR101471585B1 (fr)
CN (3) CN104817501B (fr)
AR (1) AR079008A1 (fr)
AU (1) AU2010306168B2 (fr)
BR (1) BR112012005011B8 (fr)
CA (1) CA2771665C (fr)
CO (1) CO6511248A2 (fr)
HR (1) HRP20130316T1 (fr)
IL (1) IL218256A (fr)
MA (1) MA33742B1 (fr)
MX (1) MX2012003050A (fr)
NZ (1) NZ598353A (fr)
PT (1) PT2488169E (fr)
SG (1) SG178835A1 (fr)
TW (1) TWI441630B (fr)
WO (1) WO2011044962A1 (fr)
ZA (1) ZA201201892B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
EP2311446A1 (fr) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
CN107648228A (zh) * 2017-10-24 2018-02-02 珠海赛隆药业股份有限公司 一种帕瑞昔布钠与盐酸曲马多组成的复合物及其用途
WO2019130049A1 (fr) 2017-12-29 2019-07-04 Grünenthal GmbH Combinaison pharmaceutique comprenant du chlorhydrate de tramadol à libération prolongée et de l'étoricoxib à libération immédiate, et son utilisation pour le traitement de la douleur
KR20220008301A (ko) * 2019-05-14 2022-01-20 에스테베 파마슈티칼스 에스에이 트라마돌의 남용 경향을 감소시키면서 통증을 치료하기 위한 트라마돌과 세레콕시브의 공-결정의 용도
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO2008085674A1 (fr) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant des co-cristaux de célécoxib
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination

Also Published As

Publication number Publication date
US20230057884A1 (en) 2023-02-23
CA2771665A1 (fr) 2011-04-21
IL218256A (en) 2017-05-29
SG178835A1 (en) 2012-05-30
CO6511248A2 (es) 2012-08-31
HRP20130316T1 (en) 2013-05-31
CN102573825B (zh) 2015-04-22
HK1173380A1 (en) 2013-05-16
CN102573825A (zh) 2012-07-11
JP2013507402A (ja) 2013-03-04
IL218256A0 (en) 2012-04-30
KR20120099212A (ko) 2012-09-07
CN104844513A (zh) 2015-08-19
ZA201201892B (en) 2012-11-28
AU2010306168B2 (en) 2014-10-30
BR112012005011B8 (pt) 2021-05-25
CN104844513B (zh) 2018-08-07
AR079008A1 (es) 2011-12-21
AU2010306168A1 (en) 2012-03-15
BR112012005011A2 (pt) 2016-05-03
BR112012005011B1 (pt) 2021-01-19
CN104817501A (zh) 2015-08-05
NZ598353A (en) 2014-01-31
CN104817501B (zh) 2017-09-22
WO2011044962A1 (fr) 2011-04-21
TW201116273A (en) 2011-05-16
PT2488169E (pt) 2013-04-03
KR101471585B1 (ko) 2014-12-10
JP5399564B2 (ja) 2014-01-29
MX2012003050A (es) 2012-05-29
CA2771665C (fr) 2015-10-06
TWI441630B (zh) 2014-06-21

Similar Documents

Publication Publication Date Title
MA34474B1 (fr) Agonistes de gpr40
McCormack Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis
UA109534C2 (uk) Співкристали трамадолу і коксибів
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA35576B1 (fr) Nouveaux composés
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TN2009000138A1 (fr) Biaryl-ether-urees
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
FR2939135B1 (fr) Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA30041B1 (fr) Immunoglobulines
ZA200800311B (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs